The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 15, 2018
Filed:
Oct. 14, 2016
Applicant:
The Regents of the University of California, Oakland, CA (US);
Inventors:
Zhenhua Li, Los Angeles, CA (US);
Arie S. Belldegrun, Los Angeles, CA (US);
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/53 (2006.01); C12N 9/88 (2006.01); C12N 5/078 (2010.01); C07K 14/535 (2006.01); G01N 33/574 (2006.01); C12N 9/96 (2006.01); A61K 38/19 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 38/193 (2013.01); A61K 45/06 (2013.01); C07K 14/535 (2013.01); C12N 5/0634 (2013.01); C12N 9/88 (2013.01); C12N 9/96 (2013.01); C12Y 402/01001 (2013.01); G01N 33/57411 (2013.01); G01N 33/57438 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55522 (2013.01); C07K 2319/75 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/24 (2013.01); C12N 2501/70 (2013.01); G01N 2333/988 (2013.01);
Abstract
This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.